<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093608</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21178</org_study_id>
    <secondary_id>KPT-IST-334</secondary_id>
    <nct_id>NCT05093608</nct_id>
  </id_info>
  <brief_title>SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>An Investigator-initiated Phase I Study of SELINEXOR in Combination With Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if the oral drug Selinexor taken&#xD;
      along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular&#xD;
      Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum Tolerated Dose (MTD) of Selinexor when combined with Bevacizumab and Atezolizumab will be determined by testing 2 dose levels. MTD reflects that highest dose that did not cause Dose Limiting Toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Objective Response (per RECIST)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Objective response is defined as the sum of complete and partial response as determined by Response Evaluation in Solid Tumors (RECIST) guidelines version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Objective Response (per mRECIST)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Objective response is defined as the sum of complete and partial response as determined by hepatocellular carcinoma modified RECIST (mRECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Progression Free Survival (PFS) defined as the time from start of treatment to documented disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall Survival (OS) defined as the time from first dose of study treatment until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg Selinexor (oral tablet) will be administered once a week continuously. Bevacizumab and atezolizumab will be administered intravenously once every 3 weeks. Each cycle length will be 21 days. On the days when Selinexor and bevacizumab/atezolizumab are given the same day, Selinexor will be administered prior to the intravenous infusions of bevacizumab and atezolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor Pill</intervention_name>
    <description>Selinexor 60 mg or 80 mg (oral table) will be administered once a week.</description>
    <arm_group_label>Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <arm_group_label>Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <other_name>Xpovio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.</description>
    <arm_group_label>Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <arm_group_label>Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <other_name>Mvasi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.</description>
    <arm_group_label>Dose Level 1 - 60 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <arm_group_label>Dose Level 2 - 80 mg Selinexor with Bevacizumab and Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines. Participants must provide informed consent prior to the first screening&#xD;
             procedure.&#xD;
&#xD;
          -  Ability to comply with the study protocol, in the investigator's judgment.&#xD;
&#xD;
          -  Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC) with&#xD;
             diagnosis confirmed by histology/cytology or clinically by American Association for&#xD;
             the Study of Liver Diseases (AASLD) criteria in cirrhotic patients. Participants&#xD;
             without cirrhosis require histological confirmation of diagnosis.&#xD;
&#xD;
          -  Disease that is not amenable to curative surgical and/or locoregional therapies, or&#xD;
             progressive disease after surgical and/or locoregional therapies.&#xD;
&#xD;
          -  No prior anti-neoplastic systemic therapy (including systemic investigational agents)&#xD;
             for HCC&#xD;
&#xD;
          -  At least 1 measurable (per RECIST v1.1) untreated lesion.&#xD;
&#xD;
          -  Participants who received prior local therapy (e.g., radiofrequency ablation,&#xD;
             percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused&#xD;
             ultrasound, transarterial chemoembolization, transarterial embolization, etc.) are&#xD;
             eligible provided the target lesion(s) have not been previously treated with local&#xD;
             therapy or the target lesion(s) within the field of local therapy have subsequently&#xD;
             progressed in accordance with RECIST version 1.1.&#xD;
&#xD;
          -  Participants must undergo an esophagogastroduodenoscopy (EGD), and all size of varices&#xD;
             (small to large) must be assessed and treated per local standard of care prior to&#xD;
             enrollment. Participants who have undergone an EGD within 6 months of prior to&#xD;
             initiation of study treatment do not need to repeat the procedure.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG ) Performance Status (PS) of ≤ 2&#xD;
&#xD;
          -  Participants with brain metastases must have treated and stable brain metastases.&#xD;
&#xD;
          -  Child-Pugh Class A within 7 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Adequate hepatic function at screening&#xD;
&#xD;
          -  Adequate renal function within 28 days prior to cycle 1 day 1&#xD;
&#xD;
          -  Adequate hematopoietic function within 7 days prior to cycle 1 day 1&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt;2+ (within 28 days of cycle 1 day 1. Patients&#xD;
             discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo&#xD;
             a 24-hour urine collection and must demonstrate &lt; 1 g of protein in 24 hours.&#xD;
&#xD;
          -  No known history of human immunodeficiency virus.&#xD;
&#xD;
          -  Documented virology status of hepatitis, as confirmed by screening HBV and HCV&#xD;
             serology test. For patients with active hepatitis B virus (HBV): HBV DNA ≤ 500 IU/mL&#xD;
             obtained within 28 days prior to initiation of study treatment, and Anti-HBV treatment&#xD;
             (per local standard of care, e.g., entecavir) for a minimum of 14 days prior to study&#xD;
             entry and willingness to continue treatment for the length of the study&#xD;
&#xD;
          -  Female participants of childbearing potential must agree to use 2 methods of&#xD;
             contraception (including 1 highly effective and 1 effective method of contraception)&#xD;
             and have a negative serum pregnancy test at Screening. Male participants must use an&#xD;
             effective barrier method of contraception if sexually active with a female of&#xD;
             childbearing potential. For both male and female participants, effective methods of&#xD;
             contraception must be used throughout the study and for 6 months following the last&#xD;
             dose of study treatment. Women of childbearing potential must have a negative serum&#xD;
             pregnancy test result within 14 days prior to initiation of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of leptomeningeal disease&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain Barré syndrome,&#xD;
             or multiple sclerosis, with the following exceptions:&#xD;
&#xD;
               -  Patients with a history of autoimmune-related hypothyroidism who are on&#xD;
                  thyroid-replacement hormone are eligible for the study.&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen&#xD;
                  are eligible for the study.&#xD;
&#xD;
               -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis are&#xD;
                  excluded) are eligible for the study provided all of following conditions are&#xD;
                  met: (a) Rash must cover ≤ 10% of body surface area (b) Disease is well&#xD;
                  controlled at baseline and requires only low-potency topical corticosteroids (c)&#xD;
                  No occurrence of acute exacerbations of the underlying condition requiring&#xD;
                  psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents,&#xD;
                  oral calcineurin inhibitors, or high-potency or oral corticosteroids within the&#xD;
                  previous 12 months&#xD;
&#xD;
          -  Prior exposure to a SINE compound, including SELINEXOR.&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan. History of&#xD;
             radiation pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
          -  Known active tuberculosis&#xD;
&#xD;
          -  Significant cardiovascular disease (such as New York Heart Association Class II or&#xD;
             greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to initiation of study treatment), unstable arrhythmia, or unstable&#xD;
             angina&#xD;
&#xD;
          -  History of congenital long QT syndrome or corrected QT interval &gt;500msec (calculated&#xD;
             with use of the Fridericia method) at screening&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that contraindicates the use of an investigational drug, may affect&#xD;
             the interpretation of the results, or may render the patient at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment, or anticipation of need for such a vaccine during atezolizumab treatment or&#xD;
             within 5 months after the last dose of atezolizumab&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies&#xD;
             or fusion proteins&#xD;
&#xD;
          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC&#xD;
&#xD;
          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or&#xD;
             high risk for bleeding. A prior bleeding event due to esophageal and/or gastric&#xD;
             varices within 6 months prior to initiation of study treatment&#xD;
&#xD;
          -  Co-infection of HBV and hepatitis C virus (HCV). Participants with a history of HCV&#xD;
             infection but who are negative for HCV RNA by polymerase chain reaction (PCR) will be&#xD;
             considered non-infected with HCV.&#xD;
&#xD;
          -  Uncontrolled tumor-related pain, symptomatic hypercalcemia (ionized calcium &gt;1.5&#xD;
             mmol/L, calcium &gt;12 mg/dL or corrected serum calcium &gt; ULN); pleural effusion,&#xD;
             pericardial effusion or ascites requiring recurrent drainage procedures. Participants&#xD;
             with indwelling catheters are allowed.&#xD;
&#xD;
          -  Treatment with investigational therapy within 28 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Treatment with strong CYP3A4 inducers within 14 days prior to initiation of study&#xD;
             treatment, including rifampin (and its analogues) or St. John's wort&#xD;
&#xD;
          -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including&#xD;
             anti-CTLA-4, anti PD-1, and anti-PD-L1 therapeutic antibodies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug&#xD;
             (whichever is longer) prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, an&#xD;
             anti-Tumor Necrosis Factor [TNF] -α agents) within 2 weeks prior to initiation of&#xD;
             study treatment, or anticipation of need for systemic immunosuppressive medication&#xD;
             during study treatment, with the following exceptions: If patient is on chronic&#xD;
             steroid prednisone equivalent less than 15 mg/day are allowed.&#xD;
&#xD;
          -  Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP)&#xD;
             ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg), based on an average of ≥ 3 BP&#xD;
             readings on ≥ 2 sessions. Anti hypertensive therapy to achieve these parameters is&#xD;
             allowable.&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  History of life-threatening bleeding within 3 months of C1D1, bleeding diathesis or&#xD;
             significant coagulopathy.&#xD;
&#xD;
          -  Current or recent (within 10 days of first dose of study treatment) use of&#xD;
             anti-platelet treatment, full-dose oral or parenteral anticoagulants or thrombolytic&#xD;
             agents for therapeutic (as opposed to prophylactic) purpose&#xD;
&#xD;
          -  History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation,&#xD;
             or intra-abdominal abscess within 6 months prior to initiation of study treatment&#xD;
&#xD;
          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction&#xD;
             including sub-occlusive disease related to the underlying disease or requirement for&#xD;
             routine parenteral hydration, parenteral nutrition, or tube feeding prior to&#xD;
             initiation of study treatment&#xD;
&#xD;
          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
          -  Metastatic disease that involves major airways or blood vessels, or centrally located&#xD;
             mediastinal tumor masses (&lt; 30 mm from the carina) of large volume&#xD;
&#xD;
          -  Participants with vascular invasion of the portal or hepatic veins may be enrolled.&#xD;
&#xD;
          -  Radiotherapy, local therapy to the liver or major surgical procedure within 28 days of&#xD;
             C1D1 of treatment.&#xD;
&#xD;
          -  Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID). Occasional&#xD;
             use of NSAIDs for the symptomatic relief of medical conditions such as headache or&#xD;
             fever is allowed.&#xD;
&#xD;
          -  Any active gastrointestinal dysfunction interfering with the patient's ability to&#xD;
             swallow tablets, or any active gastrointestinal dysfunction that could interfere with&#xD;
             absorption of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rutika Mehta, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Martinez Jimenez</last_name>
    <phone>813-745-1946</phone>
    <email>Maria.MartinezJimenez@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Martinez Jimenez</last_name>
      <phone>813-745-1946</phone>
      <email>Maria.MartinezJimenez@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Rutika Mehta, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trenton Avriett, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dae Won Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard D Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Ray, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim Sahin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

